Harnessing the Power of Nature's Designs™
Adjuvia Therapeutics
Is a preclinical-stage biopharmaceutical company committed to developing innovative, orally administered therapies for inherited and chronic diseases driven by mitochondrial and cellular dysfunction.
Our Mission
Is to improve the lives of patients with serious unmet medical needs through the development of safe, effective, and accessible treatments.
Our Vision
Is to lead in medical innovation by advancing transformative therapies that redefine care for patients affected by complex and life-threatening diseases.
United by a shared passion for improving health outcomes, we aim to deliver hope through science.
Our Science
Targeting the Root Cause of Rare and Degenerative Diseases
Mitochondrial dysfunction lies at the core of many chronic and rare diseases. It leads to excessive oxidative stress, cellular damage, and ultimately, organ failure.
Adjuvia Is Changing That
Our lead candidate, ATI-103, is a proprietary oral nanoparticle formulation of astaxanthin (ASX) — a potent, naturally occurring antioxidant with the unique ability to embed in mitochondrial membranes to protect cells from oxidative damage and regulate signaling pathways that restore cell function.
ATI-103 is currently in IND-enabling studies, well positioned to become the frontline therapy for mitochondrial disease.
Our pipeline candidate, ATI-104 to treat Alzheimer’s and other neurodegenerative diseases, is currently in preclinical POC studies.
Why ATI-103 Is Different:
Strong issued and pending IP portfolio: ASX is harvested from Haematococcus pluvialis microalgae using our issued patent method and formulated into a proprietary nanoparticle for maximal bioavailability and bioactivity.
Best-in-class mitochondrial protection: Demonstrated efficacy in diseased human cells and translational animal models.
Orally administered: Safe, scalable, and non-invasive.
High-Unmet Need Clinical Focus:
Rare Inherited Mitochondrial Diseases
Friedreich’s Ataxia: 1 in 30,000 | One approved therapy, does not address lethal heart disease | Avg. lifespan ~30 years
Leigh Syndrome: 1 in 30,000 births | Fatal in childhood | No FDA-approved treatments
Adjuvia has joined MBC BioLabs, the flagship J&J Incubator Campus in San Francisco’s vibrant Dogpatch neighborhood. Located just four blocks from UCSF, this 24,000-square-foot innovation hub has helped foster over 125 startups and continues to be a cornerstone of the Bay Area biotech community.